Natixis Sells 26,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Natixis decreased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 65.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,000 shares of the company’s stock after selling 26,000 shares during the quarter. Natixis’ holdings in Dyne Therapeutics were worth $397,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of DYN. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. boosted its position in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after buying an additional 5,541 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Dyne Therapeutics in the 4th quarter valued at $172,000. Finally, Principal Financial Group Inc. lifted its stake in Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Up 4.3 %

NASDAQ:DYN opened at $44.53 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $45.46. The firm’s 50 day moving average is $35.50 and its 200 day moving average is $28.17.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.81). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Ratings Changes

DYN has been the subject of several recent analyst reports. HC Wainwright upped their target price on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Jefferies Financial Group upped their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, May 20th. Chardan Capital lifted their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, May 21st. Morgan Stanley assumed coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price for the company. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.11.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,590 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.23, for a total transaction of $48,065.70. Following the completion of the transaction, the senior vice president now owns 115,105 shares in the company, valued at $3,479,624.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now owns 115,105 shares in the company, valued at $3,479,624.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 202,133 shares of company stock worth $6,500,387. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.